跳转至内容
Merck
所有图片(1)

文件

SML2860

Sigma-Aldrich

Triptorelin acetate

≥98% (HPLC)

别名:

6-D-Tryptophan-Luteinizing Hormone-Releasing Factor acetate, [D-Trp6]-LH-RH acetate

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C64H82N18O13 · xC2H4O2
分子量:
1311.45 (free base basis)
分類程式碼代碼:
12352200
NACRES:
NA.77

品質等級

100

化驗

≥98% (HPLC)

形狀

powder

顏色

white to off-white

儲存溫度

−20°C

生化／生理作用

Triptorelin acetate is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). It is used clinically to treat prostate cancer and precocious puberty in boys and girls.

象形圖

Health hazard
GHS08

訊號詞

Danger

危險聲明

H360D

危險分類

Repr. 1B

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Successful desensitization to gonadotropin-releasing hormone analogue triptorelin acetate using a sustained-release depot preparation.
Pauline Chan Ng et al.
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 29(6), 660-663 (2018-05-29)
Delphine Zenaty et al.
Hormone research in paediatrics, 86(3), 188-195 (2016-11-02)
To evaluate the efficacy and safety of a triptorelin pamoate (11.25 mg) 3-month formulation in the management of central precocious puberty (CPP) (TP Study) and to retrospectively compare it with a triptorelin acetate (11.25 mg) 3-month formulation (TA Study). We
Davide Meani et al.
Therapeutic advances in urology, 10(2), 51-63 (2018-02-13)
Androgen deprivation therapy (ADT) with luteinizing hormone-releasing hormone (LHRH) agonists is well established for the treatment of men with metastatic prostate cancer. As clear differences in efficacy, safety, or tolerability between the available LHRH agonists are lacking, the healthcare management

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门